Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380473 | 0.84 | ERN1 (0.57) | ERN1TDP1HSD17B10ALDH1A1PRKDC | |
| SCHEMBL1856713 | 0.82 | PTPN1 (0.45) | ERN1TDP1KDM4EALDH1A1MAPT | |
| SCHEMBL2480246 | 0.77 | XDH (0.43) | ERN1TDP1HSD17B10CYP1A2POLB | |
| SCHEMBL11252567 | 0.77 | ERN1 (0.71) | ERN1ALOX5 | |
| SCHEMBL31316334 | 0.77 | CA12 (0.47) | ERN1HDAC2KIF11 | |
| SCHEMBL609449 | 0.76 | TDP1 (0.69) | ERN1TDP1HSD17B10ALOX5AHR | |
| SCHEMBL1958671 | 0.74 | PTGS2 (0.40) | ERN1POLBMAPT | |
| SCHEMBL7841224 | 0.74 | ERN1 (0.44) | ERN1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4552823 | 0.73 | TDP1 (0.48) | ERN1TDP1HSD17B10ALOX5KDM4E | |
| SCHEMBL5736354 | 0.73 | ALOX5 (0.59) | ERN1TDP1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987476-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-8987476-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-8987476-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8680299-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8680299-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-8680299-B2 | Spiro epoxides as intermediates | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | disclosed |
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010136431-A9 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010136431-A9 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010136431-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136431-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077993-A1 | SPIRO EPOXIDES AS INTERMEDIATES | CYP1A1, CYP2E1, CYP1B1 | ERN1 1431/4885TDP1 1099/4885HSD17B10 193/4885 |
| US-20140135508-A1 | SPIRO EPOXIDES AS INTERMEDIATES | CYP1A1, CYP2E1, GSTO1 | ERN1 1441/4885TDP1 659/4885HSD17B10 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.